Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

BTKi is better: a lesson learned?

Kami Maddocks

Blood (2024) 144 (9): 926–927.

https://doi.org/10.1182/blood.2024025105

Published: 2024

Journal Articles

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood (2023) 142 (26): 2327–2331.

https://doi.org/10.1182/blood.2023021274

Published: 2023

Includes: Supplemental data

Journal Articles

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Blood (2022) 139 (13): 1999–2010.

https://doi.org/10.1182/blood.2021011894

Published: 2022

Includes: Supplemental data

Journal Articles

Building on BTK inhibition in MCL

Kami Maddocks

Blood (2021) 137 (7): 861–862.

https://doi.org/10.1182/blood.2020009781

Published: 2021

Journal Articles

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven Park, Kami Maddocks, Jia Ruan, LeAnn Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio Inghirami, Maurizio DiLiberto, Selina Chen-Kiang, John P. Leonard

Blood (2019) 133 (11): 1201–1204.

https://doi.org/10.1182/blood-2018-11-886457

Published: 2019

Journal Articles

Chemotherapy-free induction in MCL: ready for prime time?

Kami Maddocks

Blood (2018) 132 (19): 2001–2002.

https://doi.org/10.1182/blood-2018-09-875203

Published: 2018

Journal Articles

Update on mantle cell lymphoma

Kami Maddocks

Blood (2018) 132 (16): 1647–1656.

https://doi.org/10.1182/blood-2018-03-791392

Published: 2018

Journal Articles

Postibrutinib outcomes in patients with mantle cell lymphoma

Blood (2016) 127 (12): 1559–1563.

https://doi.org/10.1182/blood-2015-10-673145

Published: 2016

Journal Articles

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Blood (2016) 127 (9): 1117–1127.

https://doi.org/10.1182/blood-2015-11-679134

Published: 2016

Includes: Supplemental data

Journal Articles

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A. Jones, Joseph Flynn, Leslie A. Andritsos, Kami Maddocks, Samantha M. Jaglowski, Kristie A. Blum, John C. Byrd, Jason A. Dubovsky, Amy J. Johnson

Blood (2015) 126 (1): 61–68.

https://doi.org/10.1182/blood-2015-02-626846

Published: 2015

Includes: Supplemental data

Journal Articles

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling

Yuh-Ying Yeh, Hatice Gulcin Ozer, Amy M. Lehman, Kami Maddocks, Lianbo Yu, Amy J. Johnson, John C. Byrd

Blood (2015) 125 (21): 3297–3305.

https://doi.org/10.1182/blood-2014-12-618470

Published: 2015

Includes: Supplemental data

Journal Articles

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Ta-Ming Liu, Yonghua Ling, Jennifer A. Woyach, Kyle Beckwith, Yuh-Ying Yeh, Erin Hertlein, Xiaoli Zhang, Amy Lehman, Farrukh Awan, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Jessica MacMurray, Santosh B. Salunke, Ching-Shih Chen, Mitch A. Phelps, John C. Byrd, Amy J. Johnson

Blood (2015) 125 (2): 284–295.

https://doi.org/10.1182/blood-2014-06-583518

Published: 2015

Includes: Supplemental data

Journal Articles

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

Kami Maddocks, Beth Christian, Samantha Jaglowski, Joseph Flynn, Jeffery A. Jones, Pierluigi Porcu, Lai Wei, Cynthia Jenkins, Gerard Lozanski, John C. Byrd, Kristie A. Blum

Blood (2015) 125 (2): 242–248.

https://doi.org/10.1182/blood-2014-08-597914

Published: 2015

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Kami Maddocks, MD, Zsolt Nagy, MD, Pier Luigi Zinzani, MD PhD, Andre Goy, MD, Mariano Provencio, Tadeusz Robak, MD, Christian Buske, MD, Roman Pawel Korolkiewicz, MD, Mark Winderlich, Wojciech Jurczak, MD PhD

Blood (2014) 124 (21): 3089.

https://doi.org/10.1182/blood.V124.21.3089.3089

Published: 2014

Journal Articles

PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL

Dalia El-Gamal, Katie Williams, Taylor D. LaFollette, Matthew Cannon, James S. Blachly, Yiming Zhong, Jennifer A. Woyach, Erich Williams, Farrukh T. Awan, Jeffrey Jones, Leslie Andritsos, Kami Maddocks, Chia-Hsien Wu, Ching-Shih Chen, Amy Lehman, Xiaoli Zhang, Rosa Lapalombella, John C. Byrd

Blood (2014) 124 (9): 1481–1491.

https://doi.org/10.1182/blood-2014-05-574830

Published: 2014

Includes: Supplemental data

Journal Articles

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Blood (2014) 123 (12): 1810–1817.

https://doi.org/10.1182/blood-2013-09-527853

Published: 2014

Includes: Supplemental data

Journal Articles

B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo

Emily M. McWilliams, B.S., Carolyn Cheney, B.S, Jeffrey A. Jones, MD, MPH, Joseph M. M. Flynn, DO, MPH, Kami Maddocks, MD, Leslie A. Andritsos, MD, Heather Huet, PhD, Hermann Gram, Ph.D., Johan Baeck, MD, Natarajan Muthusamy, DVM, Ph.D, John C. Byrd, MD

Blood (2013) 122 (21): 4185.

https://doi.org/10.1182/blood.V122.21.4185.4185

Published: 2013

Journal Articles

Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype

Deborah M Stephens, DO, Amy Stark, MAS, Jeffrey A. Jones, MD, MPH, Jennifer A. Woyach, MD, Kami Maddocks, Samantha M. Jaglowski, MD, MPH, Leslie A. Andritsos, MD, Joseph M. M. Flynn, DO, MPH, Michael R. Grever, MD, Gerard Lozanski, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, Ph.D, Nyla A. Heerema, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 2872.

https://doi.org/10.1182/blood.V122.21.2872.2872

Published: 2013

Journal Articles

Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Kami Maddocks, John M. Pagel, MD, PhD, Susan O'Brien, John C. Byrd, MD, Scott Stromatt, Farrukh T Awan, MD

Blood (2013) 122 (21): 4165.

https://doi.org/10.1182/blood.V122.21.4165.4165

Published: 2013

Journal Articles

Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients

Deborah M Stephens, DO, Amy Stark, MAS, William G. Wierda, MD, PhD, Jeffrey A. Jones, MD, MPH, Jennifer A. Woyach, MD, Kami Maddocks, Samantha M. Jaglowski, MD, MPH, Leslie A Andritsos, MD, Joseph M. M. Flynn, DO, MPH, Michael R. Grever, MD, Gerard Lozanski, MD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, Susan O'Brien, MD, Michael J. Keating, MD, Natarajan Muthusamy, DVM, Ph.D, Lynne V. Abruzzo, MD, PhD, Nyla A. Heerema, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 4128.

https://doi.org/10.1182/blood.V122.21.4128.4128

Published: 2013

NARROW

BTKi is better: a lesson learned?

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Building on BTK inhibition in MCL

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Chemotherapy-free induction in MCL: ready for prime time?

Update on mantle cell lymphoma

Postibrutinib outcomes in patients with mantle cell lymphoma

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo

Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype

Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only